In a past comparison it was observed that a treatment associated auto-proliferative response in cultured peripheral blood mononuclear cells (PBMC) of asymptomatic HIV-1-infected subjects receiving a gpl20-depleted, inactivated HIV-1 antigen in incomplete Freund's adjuvant (IFA; HIV-1 Immunogen).
The frequency and magnitude of the auto-proliferative response appeared to be dose-related (P < 0-05), and was not observed in subjects receiving IFA alone. Immuno-phenotyping of the proliferating cells demonstrated the presence of both CD4+ and CD8+ lymphocytes, with the CD4+ blasts almost exclusively expressing the CD45RO+ phenotype.
A comparison of this response with the HIV- l-specific antigen stimulation responses in this cohort revealed a significant correlation between increases in HIV-1-specific cell-mediated immunity and auto-proliferation (r2=0-61, P<0-001). These findings suggest that immunization with the HIV-1 Immunogen induces an auto-proliferative response that may reflect changes in HIV-1-specific cell-mediated immunity in infected individuals.
“We are going to step up the dosing and frequency on REMUNE up from 100ug per dose every three months to 200ug once a month and 400ug every three month and see what this dynamic whole-killed vaccine really can do. REMUNE is a great drug that can eliminate the majority of the issues that plague HIV/AIDS patients. The whole-killed vaccine approach is the tried and true way of defeating a virus and we are going to hit it hard. Saving lives is important and history is proving the REMUNE skeptics wrong, Salk was a smart guy his polio vaccine didn’t get immediate raves of approval but eventually did I predict REMUNE wipes out HIV/AIDS” Mr. Buswell COO IRBP.
“Additionally we are working hard to secure funding for manufacturing and will appoint our new board members and possibly a new CEO by year end and move our clinical pipeline forward. We are on track to complete all of our goals for 2011. I am pleased with the progress we are making and look forward to banner years in the future” Mr. Buswell COO IRBP.
Full Press Release Available at www.immuneresponsebiopharma.com
Forward-Looking Statement
Some of the statements made in this press release are forward looking in nature. These statements are based on management’s current expectations or beliefs. These forward looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors, many of which are outside Immune Response BioPharma, Inc.’s control, which could cause actual events to differ materially from those expressed or implied by the statements. The most important factors that could prevent Immune Response BioPharma, Inc. from achieving its stated goals include, but are not limited to: the current uncertainty in the global financial markets and the global economy. Including but not limited to the uncertainties regarding the approval of biopharmaceutical products in a highly regulated market.
